-
Julio Morales,
Aline S de Aluja,
Jose Juan Martínez,
Marisela Hernández,
Gabriela Rosas,
Nelly Villalobos,
Beatriz Hernández, Abel Blancas,
Karen Manoutcharian,
Goar Gevorkian,
Jacquelynne Cervantes,
Alicia Díaz,
Agnes Fleury,
Gladis Fragoso,
Carlos Larralde,
Edda Sciutto
[show abstract]
[hide abstract]
ABSTRACT: This paper provides macroscopic and histological evidence on the statistically significant protective effects of S3Pvac-phage vaccination against porcine cysticercosis and hydatidosis. The study included 391 rustically bred pigs (187 vaccinated and 204 controls). Vaccination significantly reduced the prevalence of cysticercosis by 61.7%. Vaccination also significantly reduced by 56.1% the prevalence of hydatidosis caused by Echinococcus granulosus in pigs. The presence of the vaccine epitopes in both cestodes is probably involved in the cross-protection observed. Increased inflammation was found in 5% of cysticerci recovered from controls, versus 24% from vaccinated pigs (P<0.01). Hydatid cysts were non-inflammatory in either group. Vaccination was effective to prevent one single disease, but it failed to prevent the simultaneous infections with both parasites in a same pig. The widening of the S3Pvac-phage vaccine protective repertoire to include hydatidosis is a convenient feature that should reduce the prevalence of two frequent zoonoses that affect rustic porcine breading with a single action. Thus, the costs of two different vaccination programs would be reduced to a single one with significant reduction in both zoonoses.
Veterinary Parasitology 02/2011; 176(1):53-8. · 2.58 Impact Factor
-
Julio Morales,
José Juan Martínez,
Karen Manoutcharian,
Marisela Hernández,
Agnes Fleury,
Goar Gevorkian,
Gonzalo Acero, Abel Blancas,
Andrea Toledo,
Jacquelynne Cervantes,
Victor Maza,
Fabrice Quet,
Henri Bonnabau,
Aline S de Aluja,
Gladis Fragoso,
Carlos Larralde,
Edda Sciutto
[show abstract]
[hide abstract]
ABSTRACT: In search of reducing vaccine production costs', a recombinant M13 phage version of the anti-cysticercosis tripeptide vaccine (S3Pvac) was developed. The efficacy of S3Pvac-Phage vs. placebo was evaluated in a randomized trial that included 1,047 rural pigs in 16 villages of Central Mexico. Three to five months after vaccination 530 pigs were examined by tongue inspection. At 5-27 months of age, 331 pigs (197 vaccinated/134 controls) were inspected at necropsy. Vaccination reduced 70% the frequency of tongue cysticercosis and, based on necropsy, 54% of muscle-cysticercosis and by 87% the number of cysticerci.
Vaccine 07/2008; 26(23):2899-905. · 3.77 Impact Factor
-
Edda Sciutto,
Gabriela Rosas,
Marisela Hernández,
Julio Morales,
Carmen Cruz-Revilla,
Andrea Toledo,
Karen Manoutcharian,
Goar Gevorkian, Abel Blancas,
Gonzalo Acero, [......],
Raul J Bobes,
Fernando A Goldbaum,
Mirna Huerta,
Alicia Diaz-Orea,
Agnes Fleury,
Aline S de Aluja,
Jose Luis Cabrera-Ponce,
Luis Herrera-Estrella,
Gladis Fragoso,
Carlos Larralde
[show abstract]
[hide abstract]
ABSTRACT: Vaccination of pigs may curtail Taenia solium transmission by reducing the number of cysticerci, the precursors of adult intestinal tapeworms in humans. Several antigen preparations induce protection against porcine cysticercosis in experimental settings but only one subunit vaccine (S3Pvac) has been tested and proved effective in the field against naturally acquired disease. Besides improving of the vaccine's effectiveness, significant reductions in production costs and in the logistics of its administration are necessary for the feasibility of nationwide control programs. This review highlights the development of several versions of S3Pvac aimed to increase effectiveness, reduce costs and increase feasibility by novel delivery systems and alternative routes of administration.
Vaccine 03/2007; 25(8):1368-78. · 3.77 Impact Factor
